Loading
GATA2 (Endothelial transcription factor GATA-2) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Myeloproliferative neoplasms, Myelodysplastic syndromes / neoplasms and 5 more.
Transcriptional activator which regulates endothelin-1 gene expression in endothelial cells. Binds to the consensus sequence 5'-AGATAG-3'.
CIViC holds 2 clinical evidence items and 0 assertions across 2 variants, naming Bortezomib and Fasudil. Open Targets scores its association with cancer at 0.84 (direct and indirect evidence; datatypes genetic literature 0.89, literature 0.98, genetic association 0.82, somatic mutation 0.95, animal model 0.57). IntOGen calls it a driver in 5 cohorts (3 activating, 1 loss-of-function), covering Acute Myeloid Leukaemia, Head and Neck Squamous Cell Carcinoma.
In plain words · GATA2 (Endothelial transcription factor GATA-2) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Myeloproliferative neoplasms, Myelodysplastic syndromes / neoplasms and 5 more.
GATA2 (Endothelial transcription factor GATA-2) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Myeloproliferative neoplasms, Myelodysplastic syndromes / neoplasms and 5 more.
Transcriptional activator which regulates endothelin-1 gene expression in endothelial cells. Binds to the consensus sequence 5'-AGATAG-3'.
No product in this corpus aims at GATA2 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA GATA2: RNA low tissue specificity; blood lineage lineage enriched (granulocytes 567 nTPM); high antibody staining in 6 normal tissues; highest cancer staining testis cancer (5 of 11 high). Distribution: 6 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Leukaemia, Myeloid neoplasms, Prostate cancer, Head and neck squamous cell carcinoma, Skin cancer (all types), Lung cancer (all types)); Open Targets associates it with 4 specific cancer types at or above 0.5 (myelodysplastic syndrome, acute myeloid leukemia, leukemia, acute myeloid, susceptibility to, prostate carcinoma). (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P23769; CIViC gene GATA2; IntOGen GATA2; Human Protein Atlas GATA2 tissue; Open Targets ENSG00000179348 associations
First described 1991. Earliest sequence paper UniProt cites for the protein: Lee M.-E. et al, J. Biol. Chem, 1991, "Cloning of the GATA-binding protein that regulates endothelin-1 gene expression in endothelial cells". Source.
Sources: HGNC HGNC:4171 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P23769 (protein name, function text, keywords and locations (REST API)); CIViC gene GATA2 (2 evidence items, 0 assertions, 2 variants; diseases: Acute Myeloid Leukaemia, Lung Adenocarcinoma (GraphQL API, CC0)); Open Targets ENSG00000179348 (association with cancer (MONDO_0004992) 0.84; per-cancer scores at or above 0.5: prostate cancer 0.57, acute myeloid leukaemia 0.76, skin cancer 0.54, myelodysplastic syndrome 0.77, myeloproliferative neoplasm 0.80, lung cancer 0.53 (GraphQL API, CC0)); IntOGen GATA2 (driver in 5 cohorts (Act 3, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Transcriptional activator which regulates endothelin-1 gene expression in endothelial cells. Binds to the consensus sequence 5'-AGATAG-3'. Location: Nucleus (UniProt). Locus 3q21.3 (HGNC).
RNA: low tissue specificity, detected in many normal tissues. Blood: lineage enriched (granulocytes 567 nTPM).
Medium: Adrenal gland, Breast, Cerebral cortex, Cervix, Endometrium, Epididymis, Fallopian tube, Gallbladder.
RNA group enriched: Bladder Urothelial Carcinoma 23 pTPM, Kidney Chromophobe 46 pTPM, Prostate Adenocarcinoma 64 pTPM, Uterine Corpus Endometrial Carcinoma 23 pTPM.
Medium only: cervical cancer, colorectal cancer, endometrial cancer, glioma.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"GATA2" OR ABSTRACT:"GATA2" OR TITLE:"GATA binding protein 2" OR ABSTRACT:"GATA binding protein 2" OR TITLE:"Endothelial transcription factor GATA-2" OR ABSTRACT:"Endothelial transcription factor GATA-2" OR TITLE:"NFE1B" OR ABSTRACT:"NFE1B") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about GATA2, not a curated reading list.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Skin cancer (all types), CIViC.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Skin cancer (all types).
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Skin cancer (all types), CIViC.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), CIViC.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Skin cancer (all types).
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), CIViC.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia, IntOGen.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Skin cancer (all types), IntOGen.